A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little | Reuters
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
The trial showed that the treatment, which is administered via injection, resulted in average weight reduction of 22% in obese and overweight patients after 36 weeks. That compares to weight gain of 2.0% among patients treated with placebo over the same period of time.
Shares were last up 10% at 11:43 a.m. London time, putting the stock on course for its biggest daily gain since August 2023.
Shares of fellow Danish obesity drug maker Zealand Pharma also tracked higher, last up 4.7%, while Zepbound-maker Eli Lilly dipped in pre-market trade.
Amycretin targets the same gut hormone that Wegovy mimics, known as GLP-1, as well as a pancreas hormone called amylin that affects hunger. Wegovy is Novo Nordisk’s flagship obesity drug while Ozempic is its diabetes treatment.
The amycretin
The trial was conducted on 125 overweight or obese patients and the most common side effects were gastrointestinal, with the vast majority being “mild to moderate in severity.”
“We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,” Martin Lange, executive vice president for development at Novo Nordisk, said in a statement.
“The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation.”
Novo is also developing an amycretin obesity pill. Early-stage trials announced in September, showed average weight loss of 13.1% after 12 weeks. The company said at the time that the treatment was safe and tolerable for patients, but included mild-to-moderate side effects.
Novo Nordisk shares skyrocketed by 10% following the release of promising early-stage trial results for their weight loss drug. The pharmaceutical company announced that the drug demonstrated significant effectiveness in reducing body weight in patients with obesity, sparking excitement among investors and analysts.
The positive trial results have fueled optimism about the potential success of the weight loss drug, which could address a significant unmet medical need in the market. Novo Nordisk’s shares surged as investors bet on the drug’s potential to become a blockbuster product and drive future revenue growth for the company.
Analysts are closely monitoring the progress of the weight loss drug as it advances through clinical trials, with many expressing confidence in its potential to become a game-changer in the obesity treatment landscape. Novo Nordisk’s shares are expected to continue to rise as more data on the drug’s efficacy and safety profile become available, positioning the company as a key player in the weight loss market.
Overall, the market response to Novo Nordisk’s weight loss drug trial results has been overwhelmingly positive, highlighting the significant potential of the drug to revolutionize the treatment of obesity and drive value for both patients and shareholders. Investors are eagerly awaiting further updates on the drug’s development, anticipating continued growth in Novo Nordisk’s share price as the drug progresses towards regulatory approval.
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks.
The primary endpoint was treatment emergent adverse events. The safety profile of amycretin was consistent with incretin-based therapies. The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity.
When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively.
“We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity,” said Martin Lange, executive vice president for Development at Novo Nordisk. “The results seen in the trial support the weight lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation.”
Based on the results, Novo Nordisk is now planning further clinical development of amycretin in adults with overweight or obesity.
About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is developed for oral and subcutaneous administration.
About the Phase 1b/2a subcutaneous amycretin trial The trial was a randomised, placebo-controlled and double-blinded study assessing the safety, tolerability, pharmacokinetics, and proof-of-concept after subcutaneous administration of amycretin in people with overweight or obesity. The trial was conducted in 5 parts: A single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B). Lastly, in the proof-of-concept part, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).
About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Instagram, X, LinkedIn andYouTube.
Contacts for further information
Company announcement No 4 / 2025
1 If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations.
Attachment
Novo Nordisk, a leading global healthcare company, has announced the successful completion of a phase 1b/2a trial with their innovative subcutaneous amycretin treatment in individuals with overweight or obesity.
Amycretin is a novel compound that targets key mechanisms involved in weight regulation, offering a promising new approach to tackling the growing global epidemic of obesity. The trial results have shown encouraging efficacy and safety profiles, paving the way for further development of this potential game-changing therapy.
The successful completion of this trial marks an important milestone for Novo Nordisk in their mission to provide innovative solutions for individuals struggling with overweight or obesity. With obesity rates on the rise worldwide, the need for effective and safe treatments has never been more urgent.
Novo Nordisk remains committed to advancing research and development in the field of obesity management, and looks forward to bringing amycretin one step closer to becoming a reality for patients in need. Stay tuned for more updates on this exciting development in the fight against obesity.
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 10 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss treatments.
The early stage trial found that people treated with amycretin lost up to 22 per cent of their body weight after using the drug for 36 weeks.
Martin Lange, executive vice-president for development at Novo Nordisk, said the group was “very encouraged” by the results of the amycretin trial for people who are overweight or obese.
The shares rose 10 per cent to DKr636 on Friday.
The company is now planning further development of the drug, which targets two key hormones — GLP-1, which is targeted by the existing weight loss drugs, and amylin, which is believed to make people feel fuller.
Novo Nordisk had already completed an early stage trial of a pill that uses this mechanism, which showed average weight loss of about 13 per cent of body weight after 12 weeks. The latest trial, which involved 125 people, tested an injected version.
The potential drug is still many years away from the market and will need to be tested on thousands of people to prove its efficacy.
Novo Nordisk’s shares have risen in recent years as investors bet on a strong future for its weight loss and diabetes treatments, which include Wegovy and Ozempic. They reached a peak of DKr1028 last summer but have fallen sharply since then.
Last month the price declined after disappointing results from late stage trials of CagriSema, another weight loss treatment, while earlier this month the shares were hit by fears that its drugs could face price cuts in the US.
The Danish drugmaker is competing against US rival Eli Lilly in the obesity drugs market. Eli Lilly’s diabetes drug Mounjaro and weight loss treatment Zepbound offer a greater average weight loss than Novo Nordisk’s Wegovy.
Investors are looking to potential drugs in Novo Nordisk’s pipeline to see if they can beat the total weight loss of more than 22 per cent offered by Lilly’s treatments.
Novo Nordisk shares soared today after the pharmaceutical company announced positive results from a new clinical trial. The trial, which tested a potential new treatment for diabetes, showed promising outcomes for patients, with significant improvements in blood sugar levels and overall health.
Investors responded enthusiastically to the news, sending Novo Nordisk shares up by 5% in early trading. The company’s stock price has been steadily climbing in recent months, as investors eagerly anticipate the release of new products and treatments.
Novo Nordisk is known for its innovative approach to diabetes care, and this latest trial further solidifies its reputation as a leader in the field. With the global prevalence of diabetes on the rise, the demand for effective treatments continues to grow, making Novo Nordisk a key player in the healthcare industry.
Analysts are optimistic about the future of Novo Nordisk, predicting continued growth and success as the company continues to develop groundbreaking treatments for diabetes and other chronic conditions. As the market responds positively to these latest trial results, Novo Nordisk is poised for even greater success in the months and years to come.
Price: $58.00 (as of Jan 23,2025 23:16:06 UTC – Details)
From the brand
Shop First Care
Shop Gentle Cleansers
Shop Advanced Lip Care
Product Dimensions : 7.7 x 1.56 x 7.09 inches; 10.41 ounces Item model number : FJFIEJFOK619 Department : Unisex Manufacturer : AmazonUs/14QED ASIN : B09VPH7RJ3 Country of Origin : Korea, Republic of
Customers say
Customers appreciate the skin serum’s effectiveness for cleansing, toning, and moisturizing mature skin. They find it leaves their skin feeling soft, velvety, and luxurious. Many are satisfied with their skin tone, quality, and suppleness. However, some have differing opinions on value, size, and moisturizing ability.
AI-generated from the text of customer reviews
Looking to try out the amazing products from Sulwhasoo but not sure where to start? Look no further than the Sulwhasoo First Care Trial Kit! This kit is the perfect introduction to Sulwhasoo’s luxurious skincare line, featuring their iconic First Care Activating Serum.
Inside the kit, you’ll find deluxe samples of some of Sulwhasoo’s best-selling products, including the First Care Activating Serum, Essential Balancing Water, Essential Balancing Emulsion, and Concentrated Ginseng Renewing Cream. These products work together to hydrate, nourish, and revitalize your skin, leaving it looking radiant and youthful.
Whether you’re new to Sulwhasoo or a long-time fan looking to refresh your skincare routine, the First Care Trial Kit is a great way to experience the magic of Sulwhasoo’s products. Try it out today and see the difference for yourself!
#Sulwhasoo #Care #Trial #Kit,korean skin care
Dogwood Therapeutics (NASDAQ: DWTX) announced plans to begin patient dosing in Q1 2025 for its Phase 2b clinical trial (HALT-CINP) evaluating Halneuron®, a first-in-class Nav 1.7 inhibitor for treating chemotherapy-induced neuropathic pain (CINP). The drug has shown promising results in previous trials, demonstrating statistically significant reduction in cancer-related pain with an acceptable safety profile across over 700 patients, and importantly, shows no addiction potential.
The company is targeting a significant unmet medical need, as one-third of patients treated with certain chemotherapeutics develop chronic painful neuropathy, with no currently approved treatments. The CINP market is valued at approximately $1.5B, representing a substantial opportunity for Dogwood Therapeutics.
Dogwood Therapeutics (NASDAQ: DWTX) ha annunciato piani per iniziare la somministrazione ai pazienti nel primo trimestre del 2025 per il suo studio clinico di fase 2b (HALT-CINP) che valuta Halneuron®, un inibitore di Nav 1.7 innovativo per il trattamento del dolore neuropatico indotto da chemioterapia (CINP). Il farmaco ha mostrato risultati promettenti in trial precedenti, dimostrando una riduzione statisticamente significativa del dolore correlato al cancro con un profilo di sicurezza accettabile su oltre 700 pazienti e, soprattutto, non presenta potenziale di dipendenza.
L’azienda mira a soddisfare un’importante esigenza medica insoddisfatta, poiché un terzo dei pazienti trattati con certi chemioterapici sviluppa neuropatia dolorosa cronica, senza trattamenti attualmente approvati. Il mercato CINP è valutato a circa 1,5 miliardi di dollari, rappresentando un’opportunità significativa per Dogwood Therapeutics.
Dogwood Therapeutics (NASDAQ: DWTX) anunció planes para comenzar la administración de pacientes en el primer trimestre de 2025 para su ensayo clínico de fase 2b (HALT-CINP) que evalúa Halneuron®, un inhibidor de Nav 1.7 de primera clase para el tratamiento del dolor neuropático inducido por quimioterapia (CINP). El medicamento ha mostrado resultados prometedores en ensayos anteriores, demostrando una reducción estadísticamente significativa en el dolor relacionado con el cáncer con un perfil de seguridad aceptable en más de 700 pacientes y, lo que es más importante, no muestra potencial de adicción.
La empresa está abordando una necesidad médica no satisfecha significativa, ya que un tercio de los pacientes tratados con ciertos quimioterapéuticos desarrolla neuropatía dolorosa crónica, sin tratamientos actualmente aprobados. El mercado de CINP se valora en aproximadamente 1.5 mil millones de dólares, lo que representa una oportunidad sustancial para Dogwood Therapeutics.
Dogwood Therapeutics (NASDAQ: DWTX)는 화학요법 유도 신경병증(CINP) 치료를 위한 첫 번째 클래스의 Nav 1.7 억제제인 Halneuron®의 2b상 임상 시험(HALT-CINP)에서 환자 대상 투약을 2025년 1분기부터 시작할 계획이라고 발표했습니다. 이 약물은 이전 임상 시험에서 유망한 결과를 보였으며, 700명 이상의 환자에서 암 관련 통증의 통계적으로 유의미한 감소를 보여주었고, 수용 가능한 안전성 프로필을 갖추고 있으며, 중요한 점은 중독 가능성이 없음을 나타냅니다.
회사는 특정 화학요법제 치료를 받은 환자의 3분의 1이 만성 통증성 신경병증을 개발하고 있으며, 현재 승인된 치료가 없기 때문에 상당한 unmet medical need를 목표로 하고 있습니다. CINP 시장은 약 15억 달러로 평가되며, Dogwood Therapeutics에게는 상당한 기회를 나타냅니다.
Dogwood Therapeutics (NASDAQ: DWTX) a annoncé des plans pour commencer l’administration aux patients au premier trimestre de 2025 pour son essai clinique de phase 2b (HALT-CINP) évaluant Halneuron®, un inhibiteur de Nav 1.7 de première classe pour traiter la douleur neuropathique induite par chimiothérapie (CINP). Le médicament a montré des résultats prometteurs lors d’essais précédents, démontrant une réduction statistiquement significative de la douleur liée au cancer avec un profil de sécurité acceptable chez plus de 700 patients et, surtout, ne montre aucun potentiel d’addiction.
L’entreprise cible un besoin médical largement insatisfait, car un tiers des patients traités avec certains chimiothérapeutiques développent une neuropathie douloureuse chronique, sans traitements actuellement approuvés. Le marché de la CINP est évalué à environ 1,5 milliard de dollars, représentant une opportunité substantielle pour Dogwood Therapeutics.
Dogwood Therapeutics (NASDAQ: DWTX) hat Pläne angekündigt, im ersten Quartal 2025 mit der Patientendosierung für seine Phase-2b-Studie (HALT-CINP) zu beginnen, die Halneuron®, einen erstmaligen Nav 1.7-Inhibitor zur Behandlung von chemotherapiebedingten neuropathischen Schmerzen (CINP), evaluiert. Das Medikament hat in früheren Studien vielversprechende Ergebnisse gezeigt und eine statistisch signifikante Reduktion von krebserkrankungsbedingten Schmerzen bei einem akzeptablen Sicherheitsprofil in über 700 Patienten demonstriert und zeigt zudem kein Suchtpotential.
Das Unternehmen zielt auf einen erheblichen nicht erfüllten medizinischen Bedarf ab, da ein Drittel der Patienten, die mit bestimmten Chemotherapeutika behandelt werden, an chronischer schmerzhafter Neuropathie leidet, ohne dass derzeit zugelassene Behandlungen existieren. Der CINP-Markt wird auf etwa 1,5 Milliarden US-Dollar geschätzt, was eine erhebliche Möglichkeit für Dogwood Therapeutics darstellt.
Safety profile validated across 700+ patients with no addiction potential
Targeting $1.5B market opportunity in CINP
Addresses unmet medical need with no currently approved treatments
Negative
Phase 2b trial not starting until Q1 2025
Still in development stage with no approved products
Insights
The initiation of Phase 2b trials for Halneuron® represents a important milestone in addressing the significant unmet need in chemotherapy-induced neuropathic pain (CINP). The previous Phase 2 results showing statistically significant pain reduction, combined with safety data from 700+ patients and no addiction potential, positions this Nav 1.7 inhibitor as a promising non-opioid alternative.
The market opportunity is compelling – with one-third of chemotherapy patients developing chronic painful neuropathy and a similar proportion currently relying on opioids. This translates to a substantial addressable market of $1.5B. The lack of approved treatments for CINP creates a clear path to market leadership if efficacy is demonstrated.
Key differentiators include:
First-in-class Nav 1.7 specific mechanism
Non-addictive profile
Robust safety database
Strong preliminary efficacy signals
For a simpler explanation: Think of nerve pain like a faulty electrical circuit that won’t stop firing. Current treatments are like trying to fix it with duct tape – they might help temporarily but aren’t solving the real problem. Halneuron® is designed to specifically target and “turn down” the problematic circuit without affecting other important nerve functions.
This Phase 2b trial initiation signals strong commercial potential for DWTX. With a market cap of $2.49B and targeting a $1.5B market opportunity, successful trial outcomes could significantly impact valuation. The executive team’s track record with blockbuster pain medications (Celebrex, Lyrica, Savella) adds credibility to their development and commercialization capabilities.
The current standard of care relies heavily on opioids, creating an attractive market entry point for a non-addictive alternative. The lack of approved treatments for CINP presents minimal competitive barriers and potential for premium pricing. Key value drivers include:
Large addressable market with clear unmet need
Potential first-mover advantage
Strong IP position as first-in-class therapy
Experienced management team
In simpler terms: Imagine entering a market where customers desperately need your product, there’s no real competition and you have the best team to sell it. That’s essentially what Dogwood is doing with Halneuron®.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.
Halneuron® is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron® treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies, with no addiction potential.
“Chemotherapy is effective, but can be very challenging for patients given common side effects, including fever, fatigue, infection, hair loss, neuropathy and pain,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Dogwood Therapeutics, Inc. “Research suggests that one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off label treatment with available analgesics is generally not effective. Further, market data suggest that approximately one-in-three cancer patients are treated with opioids.”
“The lead Halneuron® target indication in CINP represents an area of high unmet medical need and a market valued at approximately $1.5B,” said Greg Duncan, Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc. “The Dogwood executive team has established a track record of developing and/or commercializing blockbuster medicines, including the pain therapeutics Celebrex, Lyrica and Savella.”
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron® which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo clinical trials and in both cases demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Contact:
IR@dwtx.com
FAQ
When will Dogwood Therapeutics (DWTX) begin Phase 2b trial dosing for Halneuron?
Dogwood Therapeutics plans to begin patient dosing in its Phase 2b HALT-CINP trial in the first quarter of 2025.
How many patients have been treated with Halneuron in previous clinical trials?
Halneuron has been evaluated in over 700 patients across Phase 1 and Phase 2 studies.
What is the market size for chemotherapy-induced neuropathic pain that DWTX is targeting?
The CINP market that Dogwood Therapeutics is targeting is valued at approximately $1.5B.
What percentage of chemotherapy patients develop chronic painful neuropathy?
According to the press release, one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy.
Does Halneuron show addiction potential in clinical trials?
No, Halneuron has shown no addiction potential in its clinical trials.
Dogwood Pharmaceuticals, a leading biotech company, has announced a major breakthrough in the development of their new pain drug, Halneuron. This innovative drug, specifically designed to target breakthrough pain in cancer patients, is set to revolutionize the way we treat this debilitating symptom.
Halneuron has shown promising results in preclinical studies, demonstrating its potential to provide fast-acting and long-lasting relief for patients experiencing breakthrough pain. With the launch of their Phase 2b clinical trial, Dogwood is now one step closer to bringing this groundbreaking drug to market.
The cancer pain market is estimated to be worth $1.5 billion, and Halneuron has the potential to capture a significant share of this lucrative market. By specifically targeting breakthrough pain in cancer patients, Dogwood is addressing a critical unmet need in pain management and positioning themselves as a key player in this space.
With the launch of their Phase 2b trial, Dogwood is on track to bring Halneuron to market and provide much-needed relief to cancer patients suffering from breakthrough pain. This exciting development marks a significant milestone for the company and reinforces their commitment to innovation in the field of pain management. Stay tuned for updates on the progress of this groundbreaking drug as it moves closer to commercialization.
MEDI PEEL Peptide 9 Volume Bio Tox Trial Kit 4 Items Elasticity K-Beauty
Price : 21.98
Ends on : N/A
View on eBay
Looking to improve your skin’s elasticity and overall appearance? Look no further than the MEDI PEEL Peptide 9 Volume Bio Tox Trial Kit! This 4-item set is designed to target signs of aging and promote a more youthful complexion.
Containing powerful peptides and bioactive ingredients, this K-Beauty kit helps to firm and tighten the skin, reducing the appearance of fine lines and wrinkles. The lightweight formulas are easily absorbed, leaving your skin feeling hydrated and refreshed.
Experience the benefits of MEDI PEEL’s innovative skincare technology with this trial kit. Give your skin the boost it needs to look its best!
#MEDI #PEEL #Peptide #Volume #Bio #Tox #Trial #Kit #Items #Elasticity #KBeauty,niacinamide
Price: $519.99 (as of Jan 21,2025 15:57:55 UTC – Details)
Processor: Intel Celeron J4025 (2.0 GHz base frequency, up to 2.9 GHz, 4 MB L2 cache, 2 cores) Graphics : Integrated Intel Graphics Operating system: Windows 11 Pro Memory: Up to 64 GB DDR4 Hard Drive: Up to 2 TB PCIe SSD Optical Drive: None Connectivity: 802.11a/b/g/n/ac (1×1) Wi-Fi and Bluetooth 4.2 Combo Display: 21.5″ diagonal, FHD (1920 x 1080), VA, three-sided micro-edge, anti-glare, 250 nits, 72% NTSC Audio: High Definition Audio Keyboard:Wired Keyboard & Mouse Built-in HD Webcam: HP True Vision 720p HD camera with integrated dual array digital microphones Ports: 2 x SuperSpeed USB Type-A 2 x USB Type-A 1 x HDMI 1 x Headphone / microphone combo jack 1 x RJ-45 Color: White Dimensions: 19.3 x 14.99 x 8.05 inches Weight: 12.56 lbs 【Powerful Performance】: Equipped with an Intel Celeron J4025 processor (2.0 GHz base frequency, up to 2.9 GHz) and Up to 64 GB DDR4 memory, this computer ensures smooth multitasking and efficient operation. 【Ample Storage and Fast Access】: Featuring a Up to 64GB RAM & 2 TB PCIe SSD, this system provides substantial storage space and rapid data access, enhancing overall performance 【Enhanced Connectivity and Versatility】: Includes multiple ports (2 x SuperSpeed USB Type-A, 2 x USB 2.0 Type-A, HDMI 1.4b, RJ-45, and more) for versatile connectivity options, along with built-in Wi-Fi and Bluetooth 4.2 Combo for wireless convenience. 【User-Friendly Features】: The 21.5″ FHD display with anti-glare technology, integrated HD webcam with dual array microphones, and wired keyboard & mouse make it perfect for both professional and personal use. 【Operating System & Accessories】: Windows 11 Pro – Boost productivity with pre-configured layouts to organise open apps, intuitive navigation for efficient workflows, and enhanced collaboration tools designed for seamless teamwork and multitasking, along with WOWPC recovery USB, designed to improve your troubleshooting experience with greater convenience.
Introducing the HP 22 inch All-in-One Desktop PC – the perfect solution for all your computing needs!
This 2024 latest model comes with a Microsoft Office Trial, allowing you to get started right out of the box. The Full HD display provides stunning visuals, while the 16GB of RAM ensures smooth performance for all your tasks. The 512GB PCIe SSD offers ample storage space for your files and applications, while the Intel CPU delivers powerful performance for all your computing needs.
With RJ-45 and HDMI ports, you can easily connect to your network and external devices, while the included keyboard and mouse make navigation a breeze. The WOWPC Recovery USB ensures that your system is always protected, while the Windows 11 Pro operating system provides the latest features and security updates.
Don’t settle for anything less than the best – upgrade to the HP 22 inch All-in-One Desktop PC today!
#inch #AllinOne #Desktop #Latest #Model #Microsoft #Office #Trial #FHD #Display #16GB #RAM #512GB #PCIe #SSD #Intel #CPU #RJ45 #HDMI #Keyboard #Mouse #WOWPC #Recovery #USB #Win #Pro,wowpc recovery
Netflix documentary American Manhunt: OJ Simpson is set to put the bombshell case under a new microscope.
The four-part series will dissect one of the most talked about trials in modern history: the murder trial of OJ Simpson following the deaths of his ex-wife Nicole Brown-Simpson and her friend Ronald Goldman.
NFL star Simpson was accused of double murder and was put on trial for eight months sending shockwaves through the nation.
The athlete was acquitted in October 1995 after the jury pleaded him not guilty due to creative and controversial methods used by his defence team.
Many believe the lack of knowledge of the importance of DNA testing is the reason Simpson was acquitted.
The prosecution made an infamous mistake during the trial when they asked Simpson to try on the gloves found at the scene.
They had receipts of Simpson purchasing the gloves but when he tried them on in court they did not fit, dismissing their evidence.
The prosecution argued that the gloves may have shrunk due to being held in a freezer to preserve DNA (Picture: POO/AFP via Getty Images)
Despite his acquittal, Simpson was found liable for both deaths in civil court resulting in a $33.5 million (£27.2m) payout to the victims’ families, even though he was publicly known to be in thousands of dollars worth of debt.
Simpson went on to be charged with armed robbery and kidnapping exactly 13 years after his acquittal and was sentenced to 33 years with a minimum of nine years behind bars.
The professional football player was awarded parole in 2018 and then battled with cancer which subsequently caused his death in April of last year.
TMZ reported that a source claimed that no discussions about Nicole or Ron or any ‘confession’ occurred before he died.
Simpson spent his last years in Nevada, Las Vegas (Picture: Jason Bean-Pool/Getty Images)
The new Netflix special will see some key figures reveal their account of the trial, including former LAPD detective Mark Fuhrman, Ronald Goldman`s sister Kim, the defence and prosecution lawyers Carl Douglas and Christopher Darden, as well as several witnesses.
Director Floyd Russ told Netflix: ‘Their emotions have evolved, and the way they’re able to talk about it is different than they ever have before. That sense of reflection from the people involved was apparent from the get-go, which made us feel that this story was one that needed to be told in a new and different way.’
He went on: ‘This story has so many facets and components that, when placed in a historical context, it takes on a new shape every few years.’
Simpson also had a complicated relationship with the Kardashians.
The families got to know each other when Robert Kardashian (Kris Jenner’s late husband) was one of Simpson’s defence attorneys.
150 million people tuned in to watch the televised double-murder trial (Picture: Vince Bucci/AFP via Getty Images)
The family’s relationship disintegrated when Simpson was accused of murdering Nicole Brown-Simpson – Kris’s best friend.
Kendall Jenner took to Snapchat in 2016 to reveal her middle name, Nicole, and how she was named after her mum’s late best friend.
On 11th April 2024, when Simpson’s death was announced Kaitlyn Jenner was quick to tweet ‘Good Riddance.’
This isn’t the first show made featuring the murder trial – The People v OJ Simpson was a drama released back in 2016 in which Cuba Gooding Jr plays Simpson.
In an interview on the Late Late Show with James Cordon he said ‘as an artist it was hard, we shot takes with an innocent mindset and a guilty mindset so I could take on both personas.’
American Manhunt OJ: Simpson will be released on Netflix on January 29.
Got a story?
If you’ve got a celebrity story, video or pictures get in touch with the Metro.co.uk entertainment team by emailing us celebtips@metro.co.uk, calling 020 3615 2145 or by visiting our Submit Stuff page – we’d love to hear from you.
Netflix fans, get ready for some thrilling new content coming your way! The streaming giant is about to drop an investigation of the ‘trial of the century’ that will have you on the edge of your seat.
With a gripping storyline and a talented cast, this series promises to delve deep into the details of one of the most infamous trials in history. Get ready to uncover the truth, unravel the mysteries, and witness the drama unfold as Netflix brings this captivating story to life.
Stay tuned for more updates on the release date and be prepared to binge-watch this must-see series. Get your popcorn ready and get ready to be captivated by the ‘trial of the century’ on Netflix.
Price: $24.00 – $22.00 (as of Jan 20,2025 22:55:18 UTC – Details)
Not all skin types are the same, which is why when trying new products, we strongly advise that a small patch test is conducted before going ahead with regular usage to ensure skin compatibility. We recommend applying a small amount of the product to the testing area 24 hours in advance of normal application to check for adverse reactions. Keep out of reach of children. For external use only. Keep out of eyes. Stop use if irritation develops. Product Dimensions : 3.9 x 1.9 x 4 inches; 6.74 ounces Item model number : Torriden Manufacturer : Torriden ASIN : B0BXWXTKF7 Country of Origin : Korea, Republic of
A trial, travel skin care routine with 4 different mini-sized DIVE-IN products–Cleansing Foam, Facial Toner, Facial Serum, and Soothing Cream. [Dive-IN Cleansing Foam] is a hydrating daily face wash that keeps skin hydrated even after cleansing, prepping perfectly for your next skin care steps. [Dive-IN Facial Toner] A cult-favorite facial toner that feels like water and preps skin for more absorption. [Dive-IN Serum] Brand’s Top Selling Serum with different types of Hyaluronic Acids, creating healthy, dewy, and plumped complexion. [Dive-IN Soothing Cream] A bouncy moisturizer that finishes skin care routine by providing sufficient moisturization.
Looking for a new skincare routine that will leave your skin feeling hydrated and radiant? Look no further than the Torriden DIVE IN Trial Kit! This 4-step regimen is infused with hyaluronic acid, a powerful ingredient that helps plump and hydrate the skin.
The kit includes a foam cleanser, facial toner, serum, and cream, all designed to work together to give you glowing, healthy skin. The foam cleanser gently removes dirt and impurities from the skin, while the toner helps balance the skin’s pH levels. The serum delivers a boost of hydration and nutrients, and the cream locks in moisture for all-day hydration.
Korean skincare is known for its innovative formulas and effective results, and the Torriden DIVE IN Trial Kit is no exception. Give your skin the love and care it deserves with this daily skincare set. Dive in and discover the difference for yourself!
#Torriden #DIVE #Trial #Kit #Hyaluronic #Acid #Infused #Daily #Skincare #Kit #Step #Regimen #Foam #Cleanser #Facial #Toner #Serum #Cream #Korean #Skin #Care #Set,korean skin care
Price: $39.00 (as of Jan 20,2025 06:29:35 UTC – Details)
NoWarningApplicable Package Dimensions : 7.99 x 6.02 x 2.01 inches; 9.59 ounces UPC : 818000020979 Manufacturer : Peach & Lily ASIN : B0BKQ451Z6 Country of Origin : Korea, Republic of
Discover Skin That Glows Like Glass – Looking for skin so healthy that pores look smooth and skin looks luminous and clarified? Our Glass Skin Discovery Kit features our iconic four-step Glass Skin routine in a convenient trial size. The Perfect Gift Set – Includes Power Calm Hydrating Gel Cleanser (1.0 oz), Wild Dew Treatment Essence (1.0 oz), Glass Skin Refining Serum (0.5 oz), and Matcha Pudding Antioxidant Cream (0.67 oz). Everything you need to achieve Glass Skin. Glass Skin Routine – Step 1: Power Calm Hydrating Gel Cleanser: Dispense, lather with water, and apply to face. Rinse with water and pat dry. Step 2: Wild Dew Treatment Essence: Pat onto clean skin with hands or cotton pads. Iconic Four-Step Regimen – Step 3: Glass Skin Refining Serum: Pat onto clean, dry skin. Step 4: Matcha Pudding Antioxidant Cream: Pat or massage onto face and neck. All products can be used daily, AM and PM and are travel safe. Peach & Lily – 100% worry free, clean beauty, clinically effective, safe for sensitive skin, vegan, sustainable, and cruelty-free. Powered by Korean Beauty innovations, we help you achieve your Glass Skin goals.
Are you looking to achieve that coveted glass skin look? Look no further than the Peach & Lily Glass Skin Discovery Kit! This set includes four essential products to help you achieve a flawless complexion: a cleanser, essence, serum, and cream.
Not only is this set perfect for those looking to try out a new skincare routine, but it’s also ideal for travel and on-the-go touch-ups. Plus, all products are vegan, gluten-free, and cruelty-free, making them suitable for all skin types.
Experience the power of Korean beauty with the Peach & Lily Glass Skin Discovery Kit. Say goodbye to acne and hello to radiant, smooth skin! Grab yours today and start your journey to glass skin perfection. #PeachAndLily #GlassSkin #KoreanBeauty
#Peach #Lily #Glass #Skin #Discovery #Kit #Products #Cleanser #Essence #Serum #Cream #Facial #Skincare #Set #Acne #Routine #Trial #Travel #Size #Vegan #Gluten #Free #Cruelty #Free #Korean #Beauty,korean skin care
